Antiviral Drugs on the Treatment of SARS-CoV-2 (FavRem)

August 1, 2023 updated by: Aidos Konkayev, Astana Medical University

A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs

Study Type

Observational

Enrollment (Actual)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Kazakhstan
      • Astana, Kazakhstan, 010000
        • Aidos Konkaev
      • Semey, Kazakhstan, 071407
        • Semey Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients with previous covid 19 pneumonia

Description

Inclusion Criteria:

main group

  • Patients with COVID19 with medium and easy condition disease
  • take favipiravir/remdisivir control group
  • Patients with COVID19 with medium and easy condition disease
  • not take favipiravir/remdisivir

Exclusion Criteria:

  • patients younger 18
  • severe conditionis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Complications
Evaluathion
Drug: Favipiravir
Antiviral drugs
Drug: Remdesivir
Antiviral drugs
Oxygen status
Evaluathion
Drug: Favipiravir
Antiviral drugs
Drug: Remdesivir
Antiviral drugs
Oxugen support
Evaluathion
Drug: Favipiravir
Antiviral drugs
Drug: Remdesivir
Antiviral drugs

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Outcome without comlications
Time Frame: 14 days
The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2
14 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart rate
Time Frame: 14 days
Measure
14 days
SpO2
Time Frame: 14 days
Measure
14 days
Blood pressure
Time Frame: 14 days
Measure
14 days
Respiratory rate
Time Frame: 14 days
Measure
14 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Astana Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2020

Primary Completion (Actual)

July 25, 2023

Study Completion (Actual)

July 25, 2023

Study Registration Dates

First Submitted

January 22, 2021

First Submitted That Met QC Criteria

January 25, 2021

First Posted (Actual)

January 27, 2021

Study Record Updates

Last Update Posted (Actual)

August 2, 2023

Last Update Submitted That Met QC Criteria

August 1, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AMU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Retrospective study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumonia, Viral

Clinical Trials on Favipiravir

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe